Intraperitoneal Chemotherapy
Multicystic peritoneal mesothelioma treated with complete cytoreductive surgery, peritonectomy and hyperthermic intra-peritoneal chemotherapy-A case report
International Journal of Surgery Case Reports 2020 [Link] Naveen Padmanabhan, Haruaki Ishibashi, Kazurou Nishihara, Shouzou Sako, Kanji Katayama, Satoshi Wakama, Yasuyuki Kamada, Yutaka Yonemura Abstract Background: Multicystic Peritoneal mesothelioma is a rare and distinct variety of peritoneal mesothelioma with borderline malignant potential. Conventional Tumor bulking has been associated with recurrence of 45-50 %. Hence a…
Read MoreAdvances with pharmacotherapy for peritoneal metastasis
Expert Opinion on Pharmacotherapy 2020 August 12 [Link] Yutaka Yonemura, Haruaki Iahibashi, Shouzou Sako, Akiyoshi Mizumoto, Nobuyuki Takao, Masumi Ichinose, Shunsuke Motoi, Yang Liu, Satoshi Wakama, Yasuyuki Kamada, Kazurou Nishihara Abstract Introduction: A new treatment strategy involving cytoreductive surgery (CRS) combined with perioperative intraperitoneal (IP) chemotherapy was proposed in 1999 by the Peritoneal Surface Oncology…
Read MoreImpairments in Bowel Function, Social Function and Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Annals of Surgical Oncology 2020 January [Link] Zubair Bayat, Emily L Taylor, Danielle A Bischof, J Andrea McCart, Anand Govindarajan Abstract Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can be associated with decreases in quality of life (QOL). Bowel-related QOL (BR-QOL) after CRS-HIPEC has not been previously studied. The objectives of the current study…
Read MoreSurvivin Expression as an Independent Predictor of Overall Survival in Malignant Peritoneal Mesothelioma
Oncology Letters 2020 June [Link] Guozun Zhang, Dong-Liang Yang, Guoqi Zheng, Yufei Liang Abstract Malignant peritoneal mesothelioma (MPeM) is an incurable cancer strongly associated with asbestos exposure and characterised by poor prognosis. The aim of the present study was to elucidate the prognostic and predictive value of CD146 and survivin expression in MPeM. Diagnostic biopsies…
Read MoreDextrose-Containing Carrier Solution for Hyperthermic Intraperitoneal Chemotherapy: Increased Intraoperative Hyperglycemia and Postoperative Complications.
Annals of Surgical Oncology 2020 April 19 [Link] Torphy RJ, Stewart C, Sharma P, Halpern AL, Oase K, Herter W, Bartsch C, Friedman C, Del Chiaro M, Schulick RD, Gleisner A, McCarter MD, Ahrendt SA Abstract PURPOSE:Intraoperative hyperglycemia is associated with infectious complications in general surgery patients. This study aimed to determine if the use…
Read MorePredictors and Outcomes of Surgery in Peritoneal Mesothelioma: an Analysis of 2000 Patients from the National Cancer Database.
Annals of Surgical Oncology 2020 January 31 [Link] Bijelic L, Darcy K, Stodghill J, Tian C, Cannon T Abstract INTRODUCTION: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare malignancy associated with poor outcomes. Recent reports have shown longer survival with radical surgery, usually combined with intraperitoneal chemotherapy. However, surgical interventions in these patients have not…
Read MoreIndications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
European Journal of Cancer 2020 January 24 [Link] Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T Abstract The purpose of the present review was to describe evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC), with cytoreductive surgery (CRS), in patients with a diagnosis of mesothelioma, appendiceal (including appendiceal mucinous neoplasm), colorectal, gastric,…
Read MoreLong-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
Surgical Endoscopy 2019 December 2 [Link] Mercier F, Jeremie G, Alyami M, Delphine V, Vahan K, Pascal R, Sylvie I, Guillaume P, Olivier G Abstract BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provide long-term survival for low-grade pseudomyxoma peritonei (PMP) and multicystic peritoneal mesothelioma (MM). Feasibility of laparoscopic CRS-HIPEC has been reported for…
Read MoreIntraperitoneal delivery of chemotherapeutic agents for the treatment of peritoneal metastases: Current challenges and how to overcome them.
Expert Opinion on Drug Delivery 2019 November 14 [Link] Sugarbaker PH Abstract Introduction: Peritoneal metastases of cancer remains a major cause of an adverse outcome and death following surgical treatment of malignancies that occur within the abdomen and pelvis. The administration of a chemotherapy solution directly into the peritoneal space has been used to improve…
Read MoreMESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.
Pleura and Peritoneum 2019 June 27 [Link] Sgarbura O, Gourgou S, Tosi D, Bakrin N, Bouazza N, Delaine S, De Forges H, Pocard M, Quénet F Abstract BACKGROUND: Malignant peritoneal mesothelioma (MPM) is a rare tumoral disease characterized by the diffuse involvement of the peritoneal serosa. The standard frontline treatment of MPM is cytoreductive surgery…
Read More